COSMO Pharmaceuticals SA (LSE:0RGI) — Market Cap & Net Worth
Market Cap & Net Worth: COSMO Pharmaceuticals SA (0RGI)
COSMO Pharmaceuticals SA (LSE:0RGI) has a market capitalization of $1.09 Billion (£809.93 Million) as of September 16, 2026. Listed on the LSE stock exchange, this UK-based company holds position #8546 globally and #31 in its home market, demonstrating a -0.90% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying COSMO Pharmaceuticals SA's stock price £53.99 by its total outstanding shares 15002100 (15.00 Million). Also see 0RGI current and non-current assets for a full breakdown of the balance sheet.
COSMO Pharmaceuticals SA Market Cap History: 2015 to 2026
COSMO Pharmaceuticals SA's market capitalization history from 2015 to 2026. Data shows change from $3.25 Billion to $1.09 Billion (-9.68% CAGR). Also see cash flow conversion of COSMO Pharmaceuticals SA for how efficiently the company converts equity into cash flow.
COSMO Pharmaceuticals SA Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how COSMO Pharmaceuticals SA's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check 0RGI stock price for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
20.21x
COSMO Pharmaceuticals SA's market cap is 20.21 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $3.28 Billion | $68.39 Million | $19.34 Million | 48.01x | 169.77x |
| 2017 | $2.91 Billion | $67.71 Million | -$32.45 Million | 42.91x | N/A |
| 2018 | $1.77 Billion | $65.62 Million | -$18.01 Million | 27.00x | N/A |
| 2019 | $1.54 Billion | $62.49 Million | -$24.42 Million | 24.71x | N/A |
| 2020 | $1.71 Billion | $60.95 Million | -$7.90 Million | 27.98x | N/A |
| 2021 | $1.32 Billion | $65.07 Million | $21.67 Million | 20.25x | 60.80x |
| 2022 | $1.24 Billion | $102.09 Million | $17.23 Million | 12.17x | 72.10x |
| 2023 | $1.03 Billion | $92.78 Million | -$4.93 Million | 11.14x | N/A |
| 2024 | $1.28 Billion | $266.79 Million | $133.24 Million | 4.81x | 9.63x |
| 2025 | $2.12 Billion | $104.85 Million | -$3.63 Million | 20.21x | N/A |
Competitor Companies of 0RGI by Market Capitalization
Companies near COSMO Pharmaceuticals SA in the global market cap rankings as of September 16, 2026. Review 0RGI tangible net assets ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to COSMO Pharmaceuticals SA by market ranking:
- Guomai Technologies Inc (SHE:002093): Ranked #8537 globally with a market cap of $1.09 Billion USD ( CN¥7.45 Billion CNY).
- Cansino Biologics Inc (SHG:688185): Ranked #8538 globally with a market cap of $1.09 Billion USD ( CN¥7.44 Billion CNY).
- RITES Limited (NSE:RITES): Ranked #8547 globally with a market cap of $1.09 Billion USD ( Rs100.52 Billion INR).
- Apex Dynamics Inc. (TW:4583): Ranked #8548 globally with a market cap of $1.09 Billion USD ( NT$34.47 Billion TWD).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #8537 | Guomai Technologies Inc | SHE:002093 | $1.09 Billion | CN¥7.39 |
| #8538 | Cansino Biologics Inc | SHG:688185 | $1.09 Billion | CN¥65.09 |
| #8547 | RITES Limited | NSE:RITES | $1.09 Billion | Rs209.15 |
| #8548 | Apex Dynamics Inc. | TW:4583 | $1.09 Billion | NT$430.00 |
COSMO Pharmaceuticals SA Historical Marketcap From 2015 to 2026
Between 2015 and today, COSMO Pharmaceuticals SA's market cap moved from $3.25 Billion to $ 1.09 Billion, with a yearly change of -9.68%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | £1.09 Billion | -48.68% |
| 2025 | £2.12 Billion | +65.25% |
| 2024 | £1.28 Billion | +24.13% |
| 2023 | £1.03 Billion | -16.81% |
| 2022 | £1.24 Billion | -5.74% |
| 2021 | £1.32 Billion | -22.73% |
| 2020 | £1.71 Billion | +10.43% |
| 2019 | £1.54 Billion | -12.85% |
| 2018 | £1.77 Billion | -39.01% |
| 2017 | £2.91 Billion | -11.51% |
| 2016 | £3.28 Billion | +1.01% |
| 2015 | £3.25 Billion | -- |
End of Day Market Cap According to Different Sources
On Sep 15th, 2026 the market cap of COSMO Pharmaceuticals SA was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.09 Billion USD |
| MoneyControl | $1.09 Billion USD |
| MarketWatch | $1.09 Billion USD |
| marketcap.company | $1.09 Billion USD |
| Reuters | $1.09 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About COSMO Pharmaceuticals SA
Cosmo N.V., a life sciences company, develops and manufactures pharmaceuticals and contracts for gastroenterology, dermatology, and health tech in Ireland and internationally. The company offers GI Genius, a computer-assisted system that uses artificial intelligence in real time to detect colorectal lesions; Winlevi, a prescription medicine used on the skin to treat acne vulgaris; Lialda/Mezavant… Read more